Corrigendum to “Empagliflozin protects against acute myocardial infarction by modulating the mTORC1–S6K pathway to drive metabolic reprogramming” Journal of Radiation Research and Applied Science, 19(2) 102321

Key Points

• This corrigendum addresses errors in reporting empirical findings on empagliflozin and its role in cardiac protection.
• Correction of previously reported data and interpretation related to the mTORC1–S6K pathway and metabolic effects.
• Clarification of mechanisms linking empagliflozin to myocardial protection.
• Empagliflozin demonstrates significant modulation of the mTORC1–S6K pathway.
• The impact of empagliflozin on metabolic reprogramming is confirmed, supporting its protective role against myocardial infarction.